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Congenital generalized lipodystrophy (Berardinelli-
Seip syndrome) was initially reported by Berardinelli
[1] and Seip [2] and is an extremely rare autosomal
recessive disorder with genetic heterogeneity. Its
prevalence has been estimated to be less than one in
one million. Three different loci (AGPAT2, BSCL2 and
CAV1), which map to chromosomes 9q34, 11q13 and
7q31, respectively, have been identified [3–5]. The
disease is characterized by a generalized lack of body
fat and extreme muscularity from birth, acromega-
loid features, hypertriglyceridemia, hepatomegaly and
insulin resistance (manifested as acanthosis nigri-
cans). The central nervous system is seldom affected,
except for the presence of mental retardation in ap-
proximately 80% of individuals with mutations in
BSCL2 [6]. Lafora disease (LD) is also an uncommon
autosomal recessive disorder that presents with
seizures, myoclonus and cognitive decline, which
develop during late childhood or adolescence. We
report a child with congenital generalized lipodys-
trophy and LD, a previously undescribed association,
and attempt to clarify the relationship between these
two diseases.
CASE PRESENTATION
An 11-year-old boy presented at our pediatric neurol-
ogy division with a 2-year history of seizures,
myoclonus, ataxia and cognitive decline. The patient
was born uneventfully to unrelated Taiwanese parents.
Generalized lipodystrophy with muscular hypertro-
phy, acromegaloid features, hepatomegaly, hirsutism,
hypertrophic cardiomyopathy, hypertriglyceridemia
(triglycerides, 6.9 mmol/L) and insulin resistance
(insulin, 450.7 pmol/L and acanthosis nigricans) had
been noted since infancy, and congenital generalized
lipodystrophy was diagnosed clinically. He was pre-
scribed diet modification (a low-fat diet) and received
regular follow-up at our pediatric genetic division.
The patient had psychomotor retardation; he started
walking at 3 and talking at 4 years of age. The condi-
tion improved gradually after he received special
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We report a patient with congenital generalized lipodystrophy who had suffered from seizures,
myoclonus, ataxia and cognitive decline since late childhood. Lafora disease was diagnosed
based on skin biopsy results, which revealed pathognomonic Lafora bodies. The results of
genetic analysis for mutations in EPM2A and EPM2B genes were negative. This is the first case
report describing an association between congenital generalized lipodystrophy and Lafora dis-
ease. Further studies focusing on the relationship between these two diseases and the identifica-
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education, and he was able to ambulate freely and
express himself in simple sentences. From the age of 
9 years, dysarthria, decreased verbal output and ataxia
were noted by his school teacher. Several months later,
he experienced tonic-clonic seizures with fever. Elec-
troencephalography (EEG) showed posteriorly dom-
inant irregular spike-wave discharges (Figure 1).
During the following 2 years, the patient developed
erratic myoclonus, global developmental regression
with loss of language and cognition, and became
bedridden. Treatment with valproate and levetirac-
etam was initiated and he was hospitalized due to
intractable seizures.
Neurological examination showed severe cognitive
impairment, frequent small-amplitude myoclonus and
few spontaneous movements. Diffuse fragmentary
myoclonus was present at rest and was exaggerated by
action and excitement. The cranial nerves were intact
and deep tendon reflexes were slightly decreased.
His head size, weight and height were normal for his
age. A general physical examination was unremark-
able except for the lipodystrophic, acromegaloid fea-
tures (including prognathism, prominent orbital ridges
and enlarged hands and feet), acanthosis nigricans
and hepatomegaly mentioned previously (Figure 2).
Examination of ocular fundi was normal. The results
of routine hematological, biochemical and metabolic
investigations, including lactate/pyruvate ratio, cop-
per, ceruloplasmin, and cerebrospinal fluid examina-
tion were within normal limits. Brain magnetic
resonance imaging scans showed mild generalized
atrophy with ventriculomegaly. EEG showed diffuse
slow background activity and absence of normal sleep
rhythms and epileptiform activity. Visual evoked
potentials showed increased bilateral P100 latency
and auditory brainstem evoked potentials revealed
bilateral poor wave responses at 90 dB click stimula-
tion. Somatosensory evoked potentials were not
investigated due to excessive myoclonus and diffi-
culty with sedation. The results of genetic studies 
for spinocerebellar ataxias and dentatorubropalli-
doluysian atrophy were negative.
LD was suspected on the basis of the clinical find-
ings. The diagnosis was confirmed following a skin
biopsy obtained from the axilla, which revealed peri-
odic acid-Schiff (PAS)-positive intracellular polyglu-
cosan inclusion bodies in the eccrine sweat gland
duct cells (Figure 3), the pathognomonic Lafora bodies.
The results of further genetic studies using sequence
Figure 1. Electroencephalogram of the 9-year-old boy after his















Figure 2. The patient, showing lipodystrophic, acromegaloid
face (including prognathism and prominent orbital ridges) and
acanthosis nigricans on the neck.
Figure 3. Skin biopsy from the axilla stained with periodic acid-
Schiff revealing Lafora bodies, the intracellular polyglucosan
inclusions (arrows), in eccrine sweat gland duct cells (400×).
analysis for mutations in EPM2A and EPM2B genes
were negative. Clonazepam, nitrazepam and lor-
azepam were prescribed in addition to valproate and
levetiracetam; chloral hydrate was also administered
as required, since the continuous myoclonus only
resolved during sleep. The patient’s myoclonus im-
proved and the frequency of seizures was reduced
under this drug regimen. The patient remained at
home in a near-vegetative state, with tracheostomy
and tube feeding.
DISCUSSION
The term progressive myoclonic epilepsy covers a
large and varied group of diseases characterized by
myoclonus, generalized tonic-clonic seizures, and
progressive neurological deterioration, which is typi-
cally accompanied by cerebellar signs and dementia.
LD, an autosomal recessive disorder, is referred to as
progressive myoclonic epilepsy type 2, and its clinical
and histopathological features were first described
by Gonzalo Lafora, a Spanish neurologist, in 1911. LD
occurs worldwide, though exact prevalence figures
are not available. Although rare in the out-bred pop-
ulations of the United States, Canada, China, and
Japan, LD is relatively common in the Mediterranean
basin including in Spain, France, and Italy, as well as
in restricted regions of central Asia, India, Pakistan,
northern Africa, the Middle East and other parts of
the world with a high rate of consanguinity [7]. To
the best of our knowledge, there have been no docu-
mented cases in Taiwan. The characteristic clinical
presentation of LD includes the onset of myoclonus,
visual hallucinations or transient blindness (occipital
seizures) and multiple seizure types in a previously
normal child. The mean age of onset is 14 years, but
ranges from 10 to 17 years [8]. Myoclonus and occipi-
tal seizures are cardinal components of LD [9]. In the
years following onset, the symptoms of LD progress
towards intractable action-sensitive and stimulus-
sensitive myoclonus, refractory seizures, psychosis,
ataxia, dysarthria, and dementia. Most patients die
within 10 years of onset, usually from complications
related to degeneration of the nervous system and
status epilepticus [8].
The diagnosis of LD depends on the presence of
pathognomonic Lafora bodies. These are PAS-positive
intracellular inclusions consisting of an abnormal form
of glycogen termed polyglucosan that accumulates in
neurons and other tissues, such as the heart, liver,
muscle, and skin sweat glands, though only the cen-
tral nervous system is clinically affected. In the skin,
Lafora bodies are found in eccrine gland duct cells and
in apocrine myoepithelial cells, and a skin biopsy is
the least invasive pathologic diagnostic method, with
very high, though not perfect, sensitivity [10–13].
Interpretation of skin biopsy findings carries a risk of
false-negative results, especially in newly sympto-
matic individuals, and a risk of false-positive results
because of the difficulty in distinguishing Lafora 
bodies from normal PAS-positive polysaccharides in
apocrine glands in axillary or genital biopsies [12,14].
The biopsy in our patient came from the axilla and
revealed PAS-positive inclusions in the eccrine gland
duct cells, which could be identified as unmistakable
Lafora bodies. To confirm our diagnosis, we reviewed
the related literature to identify any other conditions
associated with similar inclusion bodies; similar PAS-
positive inclusions occurred in the human brain,
called corpora amylacea, and in hepatocytes due to
medication effects in one case [15], but no such bodies
were reported in the skin. Lafora bodies also resem-
ble the polyglucosan bodies found in glycogen storage
disease type IV and adult polyglucosan body dis-
ease, but the clinical presentations are different.
Therefore, the specific skin pathology provides a 
reliable diagnosis of LD: PAS-positive inclusion bod-
ies in a previously normal child between 6 and 18
years of age with myoclonic epilepsy are pathogno-
monic of LD [9].
LD is genetically heterogeneous with at least three
loci, of which two are known, EPM2A and EPM2B
(NHLRC1). EPM2A is a four-exon gene located on
chromosome 6q24 encoding laforin, a dual-specificity
phosphatase with a carbohydrate-binding domain. It
could be involved in detecting the appearance of
polyglucosans and initiating mechanisms to eliminate
these compounds, or preventing their further forma-
tion [16]. EPM2B has a single large exon at 6p22,
which encodes the malin E3 ubiquitin ligase working
in the ubiquitin-proteasome system, the major non-
lysosomal pathway for intracellular protein degrada-
tion [17]. The mechanism by which mutations in
either EPM2A or EPM2B result in LD and the exact
role of the Lafora bodies in the pathogenesis of LD
requires further study. Accumulated evidence points to
LD as primarily a disorder of cell death with impaired
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clearance of misfolded proteins, though the mecha-
nism of polyglucosan inclusion body accumulation
remains unknown. Laforin and malin interact and
their primary roles appear to be in protecting tissues
from accumulating polyglucosans by regulating the
proteins involved in glycogen metabolism [18–21].
Several studies are investigating the biochemical path-
ways that connect laforin and malin to polyglucosan
synthesis or degradation [22].
More than 90% of LD patients can be shown to har-
bor mutations in EPM2A or EPM2B [23]. The remain-
ing patients, such as our patient, may have mutations
in noncoding regions or in a third, as yet unidentified,
gene [24]. Laboratories offering genetic testing for LD
currently use only sequencing, and a mutation that
cannot be amplified by polymerase chain reaction
would therefore remain undetected. Subsequent link-
age and haplotype analyses should therefore be per-
formed in some patients and efforts should be made to
map the third LD locus. These results suggest that,
despite advances in our understanding of the genetics
of LD, skin biopsy remains a primary diagnostic
modality and the current gold standard, since the
number of different mutations is large and mutation
detection requires genetic technology not routinely
available outside research laboratories.
To the best of our knowledge, no direct associa-
tion between these two rare diseases, congenital gen-
eralized lipodystrophy and LD, has been described.
LD is a genetic disorder of carbohydrate metabolism,
while lipodystrophy is associated with insulin resist-
ance and its complications, though any interaction
between their pathogeneses remains unclear. Some
studies have shown that some functions of the endo-
plasmic reticulum, such as protein synthesis and the
secretion and degradation of any misfolded proteins,
may be deranged in hyperglycemic patients with
lipodystrophies [25]. Interestingly, Lafora bodies are
endoplasmic reticulum-associated polyglucosan dep-
ositions. Nevertheless, further studies are needed to
clarify the relationship between these two diseases.
The prognosis of LD is presently poor, and treat-
ment remains palliative. Antiepileptic drugs, including
valproate, benzodiazepines (especially clonazepam),
levetiracetam, piracetam and zonisamide are com-
monly used for the management of seizures and
myoclonus. There is a risk of overmedication when
treating drug-resistant myoclonus. Phenytoin, viga-
batrin, carbamazepine, gabapentin, and probably
lamotrigine, should be avoided to prevent worsening
of myoclonus [26]. The promising ketogenic diet used
for LD was not suitable for our lipodystrophic patient.
Experiments to replace EPM2A using immunoliposo-
mal vectors are currently in progress [22]. Better
understanding of the pathogenetics of LD may allow
the development of gene-replacement therapies, which
could improve the prognosis for patients with LD.
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診斷為 Lafora氏症，做基因序列分析並未發現 EPM2A及 EPM2B之基因突變。之
前的文獻並未報告過此類合併先天性全身脂質營養不良症與 Lafora氏症的案例，而
本病例為首例；至於兩者間是否有關聯性以及如何確認 Lafora氏症的第三個基因位
點仍待進一步的研究。
關鍵詞：Lafora氏症，脂質營養不良症，肌陣攣，進行性肌陣攣癲癇症
(高雄醫誌 2009;25:663–8)
